Haythem Y Ali

Clinical trials

• HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

  Principal investigator · Completed · Early phase 1

  Henry Ford Health System

  2019–2024
• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

  Principal investigator · Terminated · Phase 2, Phase 3

  Henry Ford Health System

  2007–2012
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2037
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

  Site PI · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2023–2032